Pharmaceutical Business & Health Care 2014


Creating a New Industrial Culture

  • October 09, 2014
Investments by Russian and foreign partnerships are reshaping the industry, according to Vladimir Shipkov, Executive Director of the Association of International Pharmaceutical Manufacturers. He spoke to Vladimir Kozlov.

Generics Bring Vital Treatment to the Healthcare Market

  • October 08, 2014
Ranbaxy helped popularize generic alternatives on the Russian market. Aman Khanna, Country Head, Russia, Ranbaxy, told Mark Gay about his strategy.

Pharmaceuticals Among Fastest-Growing Industries

  • October 08, 2014
A darling of foreign investors, the automobile industry is withering amid the general economic slowdown, but another star, pharmaceuticals, is on the horizon.

Pharma 2020 and Import Substitution

  • October 08, 2014
$4.8 billion government program aims to boost the local production of drugs to at least 50 per cent of consumption.

Leading Firms Seek a Cure for Rare Diseases

  • October 08, 2014
Drugs companies, patients' groups and regulators work together to treat ailments in the low-volume market.

High Potential for New Products

  • October 08, 2014
NovaMedica is a $760 million joint venture between Rusnano and Domain Associates to develop new drugs in Russia. It's managed by RMI Partners. Anatoly Medetsky spoke to CEO Vladimir Gurdus.

Low Prices Limit Innovation

  • October 08, 2014
The average price of domestic drugs on the russian market is a quarter of that of imports, partly due to legacy products.
Pharmaceutical Business & Health Care 2014
Pharmaceutical Business & Health Care 2014
A darling of foreign investors, the automobile industry is withering amid the general economic slowdown, but another star, pharmaceuticals, is on the horizon. The value of medicines produced last year increased 13 per cent, compared to the previous year, according to Industry and Trade Minister Denis Manturov.
/upload/005/Pharma_2014.pdf
PDF Download PDF Version